FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C.	20549	
-------------	------	-------	--

	Washington, D	.C. 20549	
STATEMENT C	OF CHANGES IN	BENEFICIAL	OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response.									

					or S	ectic	on 30(h) o	of the	Ínvestment	Cor	npany Act	of 1940							
							lame and Ticker or Trading Symbol <u>Therapeutics, Inc.</u> [ITOS]							k all appli	cable)	Reporting Person(s) to Issi able)			
(Last)	(Fi	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/13/2023										(give title		Other (s below)	·
C/O ITEOS THERAPEUTICS, INC. 4. If Amendment, Date of Original Filed (Month/Day/Year) 321 ARSENAL STREET							6. Individual or Joint/Group Filing (Check Applicable Line)												
(Street) WATER	ГОWN M	1A 02472							Λ	X Form filed by One Reporting Person Form filed by More than One Reporting Person									
(City)	(S	tate)	(Zip)		$ _{\square}$	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								ed to					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				Execution Date		Date,	r, Transaction Disposed Code (Instr. 5)		rities Acquired (A) d Of (D) (Instr. 3, 4		, 4 and Securiti Benefic Owned		ies For ially (D) Following (I) (rm: Direct () or Indirect ((Instr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	ount (A) or (D)		e	Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/\)	ate, T	Code (Ins				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		E	3. Price of Derivative Security Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				c	Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amour or Number of Shares	er					
Stock Option (Right to Buy)	\$14.77	06/13/2023			A		22,383		06/13/2024	00	6/13/2033	Common Stock	22,38	3	\$0.00	22,383		D	

Explanation of Responses:

Remarks:

/s/ Adi Osovsky, as Attorney-

in-Fact

** Signature of Reporting Person

06/15/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).